Preferred Label : burosumab;
Obsolete resource : false;
CISMeF synonym : KRN23 monoclonal antibody;
Related MeSH term : burosumab-TWZA; KRN23 monoclonal antibody; KRN-23;
UNII : G9WJT6RD29;
Origin ID : C000601956;
UMLS CUI : C4301607;
ATC code(s)
- MeSH term(s) associated for indexing
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3490824/fr/crysvita-burosumab-hypophosphatemie-liee-a-l-x
2024
false
false
false
France
child
adolescent
treatment outcome
insurance, health, reimbursement
rickets, X-Linked hypophosphatemic
burosumab
injections, subcutaneous
antibodies, monoclonal, humanized
evaluation of the transparency committee
burosumab
familial hypophosphatemic rickets
X-Linked Dominant Hypophosphatemic Rickets
---
https://www.has-sante.fr/jcms/p_3449778/fr/crysvita-burosumab-hypophosphatemie-liee-au-fgf23
2024
false
false
false
France
French
evaluation of the transparency committee
burosumab
---
https://www.has-sante.fr/jcms/p_3550922/fr/crysvita-burosumab-maladie-osseuse
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
burosumab
FGF23-related hypophosphataemia
hypophosphatemia
X-linked hypophosphatemia
child
adolescent
adult
Oncogenic hypophosphatemic osteomalacia
Phosphaturic Mesenchymal Tumor
evaluation of the transparency committee
burosumab
bone diseases
---
https://ansm.sante.fr/tableau-acces-derogatoire/crysvita
2023
false
false
false
France
French
drug information
burosumab
burosumab
FGF23-related hypophosphataemia
Oncogenic hypophosphatemic osteomalacia
hypophosphatemia
---
https://www.has-sante.fr/jcms/p_3408892/fr/crysvita-burosumab-hypophosphatemie-liee-au-fgf23-chez-les-patients-ages-d-1-an-et-plus
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
burosumab
burosumab
injections, subcutaneous
infant
child
adolescent
adult
Phosphaturic Mesenchymal Tumor
oncogenic osteomalacia
hypophosphatemia
Fibroblast Growth Factor-23
FGF23-related hypophosphataemia
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3359159/fr/crysvita-burosumab-hypophosphatemie-liee-au-fgf23
https://www.has-sante.fr/jcms/p_3359197/fr/decision-n2022-0274/dc/sem-du-21-juillet-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-crysvita
2022
false
false
false
France
injections, subcutaneous
treatment outcome
insurance, health, reimbursement
child
adolescent
adult
Fibroblast Growth Factor-23
Phosphaturic Mesenchymal Tumor
oncogenic osteomalacia
guidelines for drug use
summary of product characteristics
package leaflet
burosumab
evaluation of the transparency committee
burosumab
hypophosphatemia
---
https://www.has-sante.fr/jcms/p_3236700/fr/crysvita
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
burosumab
rare diseases
adolescent
adult
X-linked hypophosphatemia
familial hypophosphatemic rickets
burosumab
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3273465/fr/crysvita-burosumab-hypophosphatemie-liee-a-l-x-pediatrie-et-adultes
2021
false
false
false
France
burosumab
treatment outcome
insurance, health, reimbursement
burosumab
injections, subcutaneous
rickets, X-Linked hypophosphatemic
adult
child
adolescent
rare diseases
guidelines for drug use
evaluation of the transparency committee
antibodies, monoclonal, humanized
familial hypophosphatemic rickets
antibodies, monoclonal
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00429
2019
false
false
false
Canada
French
drug evaluation
burosumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2900188/fr/crysvita
2019
false
false
false
France
French
treatment outcome
burosumab
orphan drug production
familial hypophosphatemic rickets
infant
child
adolescent
injections, subcutaneous
familial hypophosphatemic rickets
evaluation of the transparency committee
burosumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3098005/fr/crysvita
2019
false
false
false
France
burosumab
injections, subcutaneous
rickets, X-Linked hypophosphatemic
infant
child
adolescent
treatment outcome
insurance, health, reimbursement
burosumab
evaluation of the transparency committee
familial hypophosphatemic rickets
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.ema.europa.eu/medicines/human/EPAR/Crysvita
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
treatment outcome
burosumab
orphan drug production
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
familial hypophosphatemic rickets
infant
child
adolescent
injections, subcutaneous
product surveillance, postmarketing
continuity of patient care
familial hypophosphatemic rickets
drug interactions
drug evaluation, preclinical
burosumab
burosumab
antibodies, monoclonal
antibodies, monoclonal
Fibroblast Growth Factor-23
---
